Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-125662
Abstract: Introduction: On November 2018 the FDA approved the treatment of venetoclax together with hypomethylating agent (HMA) or low dose cytarabine (LDAC) for newly diagnosed AML patients who cannot tolerate intensive chemotherapy. There is limited data… read more here.
Keywords: relapsed refractory; venetoclax; venetoclax given; intensive chemotherapy ... See more keywords